Bio-Path (BPTH) Competitors $0.07 +0.00 (+0.15%) As of 01:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. ENVB, SRNE, VCNX, EVFM, PPBT, AKAN, GRTX, SCNI, ZVSA, and ASLNShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Enveric Biosciences (ENVB), Sorrento Therapeutics (SRNE), Vaccinex (VCNX), Evofem Biosciences (EVFM), Purple Biotech (PPBT), Akanda (AKAN), Galera Therapeutics (GRTX), Scinai Immunotherapeutics (SCNI), ZyVersa Therapeutics (ZVSA), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors Enveric Biosciences Sorrento Therapeutics Vaccinex Evofem Biosciences Purple Biotech Akanda Galera Therapeutics Scinai Immunotherapeutics ZyVersa Therapeutics ASLAN Pharmaceuticals Bio-Path (NASDAQ:BPTH) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk. Which has more risk & volatility, BPTH or ENVB? Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Does the media refer more to BPTH or ENVB? In the previous week, Enveric Biosciences had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Bio-Path. Enveric Biosciences' average media sentiment score of 1.91 beat Bio-Path's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Neutral Enveric Biosciences Very Positive Do analysts rate BPTH or ENVB? Enveric Biosciences has a consensus price target of $10.00, indicating a potential upside of 1,502.56%. Given Enveric Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Enveric Biosciences is more favorable than Bio-Path.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BPTH or ENVB more profitable? Enveric Biosciences' return on equity of -341.48% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Enveric Biosciences N/A -341.48%-240.71% Which has better valuation and earnings, BPTH or ENVB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/AEnveric BiosciencesN/AN/A-$9.57M-$38.38-0.02 Do institutionals and insiders have more ownership in BPTH or ENVB? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 1.1% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryEnveric Biosciences beats Bio-Path on 11 of the 11 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$634K$831.92M$5.66B$10.36BDividend YieldN/A4.84%5.75%4.64%P/E RatioN/A1.1975.7326.10Price / SalesN/A26.28560.77125.36Price / CashN/A17.6537.6061.24Price / Book0.106.4612.376.34Net Income-$16.08M-$5.42M$3.29B$271.02M7 Day PerformanceN/A-0.77%1.14%0.20%1 Month PerformanceN/A4.60%3.68%6.18%1 Year PerformanceN/A23.61%60.77%28.37% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path0.3093 of 5 stars$0.07+0.1%N/A-92.5%$634KN/A0.0010ENVBEnveric Biosciences2.4043 of 5 stars$0.58-3.3%$10.00+1,618.2%-92.0%$1.95MN/A-0.0220SRNESorrento Therapeutics0.7147 of 5 stars$0.00-30.0%N/A+38.9%$1.93M$60.32M0.00800Gap DownVCNXVaccinex0.3079 of 5 stars$0.700.0%N/A-83.7%$1.82M$388K-0.0140Gap UpEVFMEvofem Biosciences0.4657 of 5 stars$0.01+0.7%N/A+52.2%$1.77M$11.39M-0.02120News CoveragePPBTPurple Biotech2.9309 of 5 stars$0.57-2.7%$33.00+5,717.0%-89.8%$1.77MN/A-1.3520Positive NewsAKANAkanda1.8841 of 5 stars$3.60+2.3%N/A-46.8%$1.61M$840K0.00110GRTXGalera TherapeuticsN/A$0.02+15.4%N/A-75.0%$1.59MN/A-0.0630SCNIScinai Immunotherapeutics1.5635 of 5 stars$1.45-7.6%N/A-61.4%$1.57M$660K-0.1520Gap DownHigh Trading VolumeZVSAZyVersa TherapeuticsN/A$0.16+6.7%N/A-92.0%$1.27MN/A0.002ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330 Related Companies and Tools Related Companies ENVB Alternatives SRNE Alternatives VCNX Alternatives EVFM Alternatives PPBT Alternatives AKAN Alternatives GRTX Alternatives SCNI Alternatives ZVSA Alternatives ASLN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts